Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr;13(4):1215-1224.
doi: 10.3892/etm.2017.4154. Epub 2017 Feb 22.

Early application of low-dose glucocorticoid improves acute respiratory distress syndrome: A meta-analysis of randomized controlled trials

Zhi-Gang Yang  1 , Xiao-Li Lei  1 , Xiao-Liang Li  1
Affiliations

Early application of low-dose glucocorticoid improves acute respiratory distress syndrome: A meta-analysis of randomized controlled trials

Zhi-Gang Yang et al. Exp Ther Med. 2017 Apr.

Abstract

Previous clinical trials have investigated the effect of glucocorticoid therapy in acute respiratory distress syndrome (ARDS), with controversial results, particularly with regard to the early administration of low dose glucocorticoid. The present meta-analysis aimed to assess whether the application of glucocorticoid was able to reduce mortality in patients with ARDS. A literature search was performed using online databases, including MEDLINE, Embase, Cochrane and CNKI regardless of whether the studies were published in English or Chinese. Following assessment via inclusion and exclusion criteria, two reviewers screened controlled randomized trials which investigated glucocorticoid therapy in ARDS patients and independently extracted data. The quality of all of the included trials was evaluated based on blinding, randomization and other methods. A total of 14 studies with 1,441 patients met the inclusion criteria. The results of the meta-analysis demonstrated that glucocorticoid significantly reduced the overall mortality of patients with ARDS [relative ratio (RR), 0.68; 95% confidence interval (CI), 0.50-0.91; P<0.05], particularly with a low-dose of glucocorticoid (RR, 0.57; 95% CI, 0.39-0.84; P<0.05) at the early phase of ARDS (RR, 0.37; 95% CI, 0.16-0.86; P<0.05), and a longer duration of steroids (RR, 0.44; 95% CI, 0.30-0.64; P<0.05). Administration of steroids also significantly increased the number of days that patients remained alive and were off mechanical ventilation (RR, 3.08; 95% CI, 1.49-4.68; P<0.05) without significantly increasing the novel infection rate (RR, 1.00; 95% CI, 0.44-2.25; P<0.05). Due to inconsistencies and other limitations, the quality of the studies used for the meta-analysis of the effect of glucocorticoid on mortality was low. In conclusion, early use of low dose glucocorticoid may effectively reduce mortality in patients with ARDS. However, this conclusion may be affected by the limited quality of the studies included in the present meta-analysis.

Keywords: acute respiratory distress syndrome; effect; glucocorticoid; meta-analysis; mortality.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow diagram of studies.
Figure 2.
Figure 2.
Meta-analysis of the effect of low-dose and high-dose of steroids on the mortality in patients with ARDS. ARDS, acute respiratory distress syndrome.
Figure 3.
Figure 3.
Pooled analysis of early and late administration of steroids in reducing the mortality of ARDS patients. ARDS, acute respiratory distress syndrome.
Figure 4.
Figure 4.
Effect of short (within 7 days) and long (longer than 7 days) duration of steroid treatment compared with control on the death rate.
Figure 5.
Figure 5.
Impact of steroid therapy on the days remaining alive and off ventilation.
Figure 6.
Figure 6.
Meta-analysis of administration of steroid therapy in improving the PaO2/FiO2 ratio of ARDS patients. ARDS, acute respiratory distress syndrome.
Figure 7.
Figure 7.
Meta-analysis of administration of steroid therapy in patients with the risk of a with new infection.
Figure 8.
Figure 8.
Funnel plot of studies included.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Koh Y. Update in acute respiratory distress syndrome. J Intensive Care. 2014;2:2. doi: 10.1186/2052-0492-2-2. - DOI - PMC - PubMed
    1. Del Sorbo L, Slutsky AS. Acute respiratory distress syndrome and multiple organ failure. Curr Opin Crit Care. 2011;17:1–6. doi: 10.1097/MCC.0b013e3283427295. - DOI - PubMed
    1. Guérin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, Mercier E, Badet M, Mercat A, Baudin O, et al. PROSEVA Study Group Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368:2159–2168. doi: 10.1056/NEJMoa1214103. - DOI - PubMed
    1. Mondrinos MJ, Kennedy PA, Lyons M, Deutschman CS, Kilpatrick LE. Protein kinase C and acute respiratory distress syndrome. Shock. 2013;39:467–479. doi: 10.1097/SHK.0b013e318294f85a. - DOI - PMC - PubMed
    1. Carnesecchi S, Pache JC, Barazzone-Argiroffo C. NOX enzymes: Potential target for the treatment of acute lung injury. Cell Mol Life Sci. 2012;69:2373–2385. doi: 10.1007/s00018-012-1013-6. - DOI - PMC - PubMed